Imaizumi, Satoshi http://orcid.org/0000-0003-2568-1730
,
Shiga, Yuhei
Ogawa, Masahiro
Sako, Hideto
Nagata, Yoshihisa
Matsunaga, Akira
Shirotani, Tetsuro
Hoshino, Fumihiro
Yahiro, Eiji
Uehara, Yuko
Morito, Natsumi
Tanigawa, Hiroyuki
Shimono, Dai
Fukushima, Mikio
Sugihara, Hidekazu
Norimatsu, Kenji
Kusumoto, Takaaki
Saku, Keijiro
Miura, Shin-ichiro
Funding for this research was provided by:
Dainippon Sumitomo Pharma
Article History
Received: 6 June 2018
Accepted: 26 October 2018
First Online: 8 November 2018
Change Date: 10 April 2019
Change Type: Correction
Change Date: 10 April 2019
Change Type: Correction
Change Details: In the Original publication of the article, the legend appearing inside the flow chart has been incorrectly published.
Change Details: In the Original publication of the article, the legend appearing inside the flow chart has been incorrectly published.
Compliance with ethical standards
:
: The ACADEMIE trial was sponsored by Sumitomo Dainippon Pharma Co., Ltd. K.S. is a Chief Director and S.M. is a Director of NPO Clinical and Applied Science, Fukuoka, Japan. K.S. has an Endowed “Department of Molecular Cardiovascular Therapeutics” supported by MSD, Co. LTD. S.M. belongs to the Department of Molecular Cardiovascular Therapeutics, which is supported by MSD, Co. LTD. K.S. and S.M. have received grants and lecture honoraria from Daiichi-Sankyo Co, Takeda Pharm. Co. Ltd., Bayer Yakuhin Pharm., and Astellas Pharma Inc.